Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegmolesatide in Dialysis CKD Patients With Anemia Switching From HIF-PHI
NCT07136792Recruiting
- Sponsor
- Guangdong Provincial People's Hospital
- Start
- Sep 2025
- Primary completion
- Dec 2026
- Modality
- PEGylated Peptides
- Countries
- 1
01
Overview
Randomised, open-label trial of peglmolesatide in anemia of chronic kidney disease and chronic kidney disease (CKD) (4 arms), sponsored by Guangdong Provincial People's Hospital. Primary endpoint: Change of mean Hemoglobin level at 16 weeks. Started Sep 2025; status: recruiting.
02
Drugs
peglmolesatide
03
Conditions
anemia of chronic kidney diseasechronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT07136792.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07136792.